To assess survival outcomes following high dose IL-2 (HDIL-2) in a contemporary cohort of patients during the era of targeted agents.
Retrospective review of metastatic RCC patients treated with HDIL-2 between July 2007 and September 2014. Clinicopathologic data were abstracted and patient response to therapy was based on RECIST v1.1 criteria. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) for the entire cohort, response to HDIL-2 in regards to previous targeted agent therapy, and response to targeted agent in relationship to response to HDIL-2.
Ninety-two patients were identified of which 87 had documentation of response to HDIL-2. Median OS was 34.4 months from initiation of HDIL-2 therapy for the entire cohort. Patients who received pre-HDIL-2 targeted therapy had similar OS (median 34.4 vs. 30.0 months; p=0.88) and PFS (median 1.5 vs. 1.7 months; p=0.8) compared to patients who had no prior therapy, respectively. Additionally, patients with complete or partial response to HDIL-2 had similar outcomes with subsequent targeted agents compared to patients whose best response was stable or progressive disease (median OS 30.1 vs. 25.4 months; p=0.4).
Our data demonstrate that patient response to HDIL-2 and both pre and post-HDIL-2 targeted agents are independent. As such, carefully selected patients should be offered HDIL-2 for the possibility of complete and durable response without the fear of limiting treatment benefit with targeted agents.
The Journal of urology. 2017 Mar 10 [Epub ahead of print]
Jessie Gills, William P Parker, Scott Pate, Sida Niu, Peter Van Veldhuizen, Moben Mirza, Jeffery M Holzbeierlein, Eugene K Lee